– USA, PA – NeuBase Therapeutics, Inc. (Nasdaq: NBSE), a biotechnology company accelerating the genetic revolution with a new class of precision genetic medicines, today announced the appointment of Gerry McDougall to its Board of Directors.
For more than 25 years, Mr. McDougall has been the driving force behind large-scale strategic alliances, joint ventures, and industry partnerships across the healthcare industry to advance innovations in precision medicine and cancer.
“Gerry’s deep expertise, passionate commitment to improve the human condition, and vast network have been the foundation for numerous transformational alliances in life sciences and healthcare, and his ability to create synergistic combinations of people, ideas, and resources is exceptional,” said Founder, CEO and Chairman, Dr. Dietrich Stephan. “The Board and I look forward to working closely with Gerry as we advance NeuBase’s comprehensive approach to precision genetic medicine to address previously untreatable diseases.”
About Gerry McDougall
Gerry McDougall spent almost his entire career as a senior partner at PwC where he built and led the firm’s Global Health Science consulting practice before retiring. He has worked across the entire ecosystem of the healthcare industry and advised an array of Fortune 500 companies, including leading global pharmaceutical companies. Mr. McDougall has been instrumental around the globe in building public-private partnerships to address human health imperatives. These include the creation and maturation of the Translational Genomics Research Institute, Arizona’s renowned bio-cluster; the design and launch of the Multiple Myeloma Research Consortium; the strategic plan for the California Institute of Regenerative Medicine and the Country of Luxemburg’s biotechnology commercialization ecosystem.
“Genetics are the foundation for understanding and treating rare and common diseases including cancers, and the ability to precisely modulate gene function is key to developing new medicines for the many diseases that still have no treatment options,” said Mr. McDougall. “I have dedicated my career to coalescing divergent approaches to achieve precision care, and I believe NeuBase can unify the field of precision genetic medicine with its PATrOL™ technology platform.”
About NeuBase Therapeutics, Inc.
NeuBase is accelerating the genetic revolution by developing a new class of precision genetic medicines which can be designed to increase, decrease, or change gene function, as appropriate, to resolve genetic defects that drive disease. NeuBase’s targeted PATrOL therapies are centered around its proprietary drug scaffold to address genetic diseases at the DNA or RNA level by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular, and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions.
For more information: https://www.neubasetherapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
